Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Adenosine
Drug ID BADD_D00045
Description The structure of adenosine was first described in 1931,[A229823] though the vasodilating effects were not described in literature until the 1940s.[A229828] Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy,[L31983] though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia.[L31998] Adenosine was granted FDA approval on 30 October 1989.[L31978]
Indications and Usage Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
Marketing Status Prescription; Discontinued
ATC Code C01EB10
DrugBank ID DB00640
KEGG ID D00045
MeSH ID D000241
PubChem ID 60961
TTD Drug ID D06IAR
NDC Product Code 16714-180; 67457-859; 82083-0011; 25021-301; 72211-004; 72397-010; 73590-0076; 73113-030; 82083-0008; 73590-0080; 72371-030; 68083-157; 81710-040; 73590-0040; 63323-651; 73590-0039; 73590-0035; 70930-504; 51662-1450; 17478-953; 72371-010; 67457-857; 55150-192; 62041-300; 73509-020; 73590-0038; 70930-502; 73590-0054; 23155-258; 73590-0079; 69153-070; 82083-0009; 55150-193; 73590-0037; 67457-855; 0703-8776; 51346-537; 52584-026; 12562-3021; 0409-1932; 71872-7035; 17478-544; 71080-0024; 73590-0078; 71872-7099; 81710-080; 73590-0081; 0703-8777; 71080-0027; 60611-0120; 76731-212; 68083-101; 72371-020; 74647-0005; 71711-0005; 67457-856; 51662-1345; 81710-050; 0641-6113; 81689-040; 73590-0033; 82083-0007; 68083-156; 70518-2778; 73590-0048; 73590-0036; 0404-9809; 42491-1200; 81758-010; 73590-0032; 67457-858; 73590-0051; 73590-0034; 73509-010; 62041-290; 71872-7209; 81647-150; 51662-1511; 0469-8234; 17478-542; 67457-854; 81647-130; 42491-1100; 71006-090; 73590-0077; 58623-0061; 73590-0031; 81710-020; 82428-010; 16714-972; 14593-933
Synonyms Adenosine | Adenocard | Adenoscan
Chemical Information
Molecular Formula C10H13N5O4
CAS Registry Number 5536-17-4
SMILES C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisTyrosine-protein phosphatase non-receptor type 12Q05209Not Available11000134; 12686737; 11226388; 11159014
Cell deathL-lactate dehydrogenase A chainP00338T150533261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Cytogenetic abnormalityL-lactate dehydrogenase A chainP00338T150533261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismPurine nucleoside phosphorylaseP00491T781983261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismAdenosine deaminaseP00813T036613261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismAdenosine deaminaseP00813T0366110069416; 10845921; 11435465
Disorders of purine metabolismDeoxyribonuclease-1P49183Not Available3261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
ImmunodeficiencyAdenosine deaminaseP00813T0366110069416; 10845921; 11435465
ImmunodeficiencyAdenosine deaminaseP00813T036613261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
PainP2X purinoceptor 4P51577Not Available14978347; 15469044; 12917686
PainMitogen-activated protein kinase 11Q15759T5572914978347; 15469044; 12917686
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery stenosis24.04.04.017; 02.02.01.0100.000371%Not Available
Cough22.02.03.001--
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.000927%
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspnoea22.02.01.004; 02.01.03.0020.001113%
Electrocardiogram ST segment depression13.14.05.005--Not Available
Electrocardiogram ST segment elevation13.14.05.025--Not Available
Extrasystoles02.03.02.003--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000371%
Generalised tonic-clonic seizure17.12.01.002--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Head discomfort17.02.05.027--Not Available
Headache17.14.01.001--
Heart rate abnormal13.14.04.0060.000742%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.0020.001298%
Hypoxia22.02.02.0030.000371%
Injection site reaction12.07.03.015; 08.02.03.014--
Intracranial pressure increased17.07.02.002--Not Available
Livedo reticularis24.03.04.003; 23.06.05.0010.000556%Not Available
Loss of consciousness17.02.04.0040.000371%Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages